











































Cognitive-behavioural longitudinal assessment in ALS
Citation for published version:
Poletti, B, Solca, F, Carelli, L, Faini, A, Madotto, F, Lafronza, A, Monti, A, Zago, S, Ciammola, A, Ratti, A,
Ticozzi, N, Abrahams, S & Silani, V 2018, 'Cognitive-behavioural longitudinal assessment in ALS: The
Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS)', Amyotrophic Lateral Sclerosis and
Frontotemporal Degeneration, vol. 19, no. 5-6, pp. 387-395.
https://doi.org/10.1080/21678421.2018.1473443
Digital Object Identifier (DOI):
10.1080/21678421.2018.1473443
Link:




Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Publisher Rights Statement:
This is an Accepted Manuscript of an article published by Taylor & Francis in Amyotrophic Lateral Sclerosis and
Frontotemporal Degeneration on 26/05/2018, available online:
https://www.tandfonline.com/doi/full/10.1080/21678421.2018.1473443
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
1 
 
Cognitive-behavioural longitudinal assessment in ALS: 1 
the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS) 2 
BARBARA POLETTI1¶, FEDERICA SOLCA2¶, LAURA CARELLI1, ANDREA FAINI3, FABIANA 3 
MADOTTO4, ANNALISA LAFRONZA1, ALESSIA MONTI5, STEFANO ZAGO6, ANDREA 4 
CIAMMOLA1, ANTONIA RATTI1,2, NICOLA TICOZZI1,2, SHARON ABRAHAMS7&, VINCENZO 5 
SILANI1,2& 6 
 7 
1Department of Neurology and Laboratory of Neuroscience - IRCCS Istituto Auxologico Italiano, Piazzale 8 
Brescia, 20 - 20149 Milan, Italy 9 
b.poletti@auxologico.it 10 
Tel. (+39) 02 61911.2609 11 
l.carelli@auxologico.it 12 
Tel. (+39) 02 61911.2609 13 
annalisa.lafronza@gmail.com 14 
Tel. (+39) 02 61911.2609 15 
a.ciammola@auxologico.it 16 
Tel. (+39) 02 61911.2617 17 
vincenzo@silani.com 18 
Tel. (+39) 02 61911.2982 19 
2Department of Pathophysiology and Transplantation, “Dino Ferrari” Center, Università degli Studi di Milano, 20 
Via F. Sforza, 35 - 20122 Milan, Italy 21 
federica.solca@unimi.it 22 
Tel. (+39) 02 61911.2609 23 
antonia.ratti@unimi.it 24 
Tel. (+39) 02 61911.3045 25 
nicola.ticozzi@unimi.it 26 
Tel. (+39) 02 61911.2617 27 
3Department of Cardiovascular, Neural and Metabolic Sciences - IRCCS Istituto Auxologico Italiano, Piazzale 28 
Brescia, 20 - 20149 Milan, Italy 29 
a.faini@auxologico.it 30 
Tel. (+39) 02 61911.2928 31 
4Research Centre on Public Health, Department of Medicine and Surgery, University of Milano-Bicocca, Via 32 
Cadore, 48 -20900 Monza, Italy. 33 
fabiana.madotto@unimib.it 34 
Tel. (+39) 039 233.2681 35 
5Department of  Neurorehabilitation Sciences, Casa Cura Policlinico (CCP), Via Dezza 48 - 20144 Milan, Italy  36 
alessia.monti@unitn.it  37 
Tel. (+39) 02 48593199 38 
6Department of Neuroscience and Mental Health, Università degli Studi di Milano, IRCCS Ospedale Maggiore 39 
Policlinico, Via Francesco Sforza, 35 - 20122 Milan, Italy 40 
stefano.zago@unimi.it 41 
Tel. (+39) 02 55033854 42 
7Euan MacDonald Centre for Motor Neurone Disease Research, Human Cognitive Neuroscience-Psychology, 43 
PPLS, Psychology Department, University of Edinburgh, 7 George Square - EH8 9JZ – Edinburgh, UK 44 
s.abrahams@ed.ac.uk 45 
Tel. (+44) 0131 6503339 46 
 47 
¶These authors contributed equally to this work 48 
&These authors also contributed equally to this work 49 
 50 
Running title: ECAS longitudinal assessment in ALS 51 
2 
 
Corresponding author:  1 
Barbara Poletti, PhD  2 
Department of Neurology and Laboratory of Neuroscience 3 
IRCCS Istituto Auxologico Italiano 4 
Piazzale Brescia, 20 - 20149 - Milan, Italy 5 
Phone: +39 02 619112609 6 
Fax: +39 02 619112937 7 























Abstract  1 
Objective: The study presents data on the longitudinal administration of the Italian Edinburgh 2 
Cognitive and Behavioural ALS Screen (ECAS). We investigated cognitive-behavioural 3 
performance in a group of ALS patients over time and the feasibility of repeating the ECAS 4 
longitudinally compared to standard neuropsychological tests. Finally, correlations between 5 
clinical/genetic and cognitive/behavioural data were considered.  6 
Methods: 168 ALS patients were tested at baseline (T0). Among these, 48 patients performed 7 
the ECAS after 6 months (T1), 18 patients performed it at T2 (12 months) and 5 patients were 8 
assessed after 24 months (T3). Participants were also administered two cognitive test (FAB; 9 
MoCA) and psychological questionnaires (BDI; STAI/Y). The FBI was carried out with 10 
caregivers.  11 
Results: No cognitive deterioration was found across follow-ups. In contrast, although scores 12 
did not change between T0 and T1, scores improved significantly for ECAS Total/ALS Non-13 
specific and Memory domains when the ECAS was repeated on three occasions (T0, T1, T2). 14 
Apathy/Inertia was the most common behavioural symptom, but no worsening of behavioural 15 
scores was detected over time. After 12–24 months, patients were still able to perform the 16 
ECAS in total, in contrast to FAB and MoCA, which were only partially administrable. 17 
Conclusions: The significant improvement of some ECAS scores over time supports the 18 
presence of possible practice effects, particularly in the memory domain, highlighting the 19 
need to accommodate for these in longitudinal assessments, through healthy controls groups 20 
or alternate versions. This work represents the first Italian ECAS follow-up study and 21 
confirms ECAS feasibility in patients with increasing physical disability.  22 
 23 
Keywords: ECAS; longitudinal assessment; Amyotrophic Lateral Sclerosis (ALS); cognition; 24 
behavioural change; practice effect 25 
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Introduction  1 
Cognitive-behavioural changes in patients with amyotrophic lateral sclerosis (ALS) are now 2 
fully recognized as integral elements of the disease, along a spectrum of frontotemporal 3 
dysfunctions (1, 2). In recent years, several cognitive screening tools have been developed for 4 
ALS (3-8); however, they are not designed to detect a heterogeneous cognitive involvement 5 
(9-11), nor to compensate for patients’ physical disability (6, 12, 13). In order to overcome 6 
such limitations, Abrahams et al. (14) developed a rapid cognitive-behavioural screening tool 7 
(Edinburgh Cognitive and Behavioural ALS Screen – ECAS), specifically designed to 8 
accommodate for verbal/motor disability. The ECAS has been translated (15, 16, 17) and 9 
validated against gold standard neuropsychological measures (15, 16, 18-20), showing high 10 
sensitivity and specificity (15, 18). 11 
Although the existence of cognitive-behavioural involvement in ALS is now well-established, 12 
its longitudinal evolution has been less investigated. Previous follow-up studies revealed 13 
conflicting results (21-29); however, due to the lack of verbal-motor adaptations, it is not 14 
possible to determine whether any observed deterioration was caused by increasing physical 15 
disability affecting performance or by cognitive decline. Similarly, few longitudinal studies 16 
are available on behavioural changes along the disease course (30-32). To date, only one 17 
study has focused on longitudinal assessment using the ECAS, specifically investigating a 18 
possible learning effect on ECAS repeated measurements (33); however, no data were 19 
provided about the relationship between cognitive and clinical aspects, including affective or 20 
genetic issues. Moreover, the longitudinal validity of the ECAS Behaviour Interview, also 21 
with respect to other standard tools, was not considered. The possible progression of 22 
cognitive-behavioural alterations over time represents a crucial issue, since such changes are a 23 
negative prognostic factor in ALS (34), associated with shorter survival and faster functional 24 
decline (24, 35, 36). This study aimed 1) to investigate cognitive-behavioural change in ALS 25 
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patients longitudinally; 2) to compare the feasibility of undertaking an ECAS over time 1 
against standard neuropsychological assessment tools; 3) to analyse the relationship between 2 
cognitive, behavioural and psychological aspects and clinical/genetic features.      3 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             4 
Material and methods 5 
Participants and procedure 6 
168 ALS patients, who fulfilled the revised El Escorial criteria for possible, probable, 7 
probable laboratory-supported or definite ALS (37), were recruited at the Department of 8 
Neurology, IRCCS Istituto Auxologico Italiano between May 2013 and February 2017. 9 
Patients in terminal stage of disease or with major comorbid medical, neurological, 10 
psychiatric or cardio-vascular diseases were excluded. Disease status was evaluated using the 11 
ALS Functional Rating Scale-Revised - ALSFRS-R (38). Patients were also screened for 12 
mutations in C9orf72, SOD1, TARDBP and FUS genes according to standard protocols (39, 13 
40). A subset of patients (N=107) was previously included in the Italian ECAS validation 14 
study (15).  15 
All patients were invited to take part in a longitudinal study from baseline (T0), with follow-16 
up at 6 (T1), 12 (T2) and 24 (T3) months when possible given the clinical conditions. Of the 17 
168 patients who performed the ECAS protocol at T0, 48 patients performed it at T1, while 18 18 
patients performed it also at T2. Finally, 5 patients were tested at T3; however, due to the 19 
small proportion of patients who managed to complete this 24-months follow-up, such data 20 
were not considered, due to their poor reliability. Further details are reported in Figure 1. 21 
Given the rate of attrition, the longitudinal comparison was conducted in the 48 patients who 22 
performed the ECAS at T0 and T1 and in the 18 patients who performed all the three 23 
assessment at T0, T1 and T2. 24 
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The study protocol was reviewed and approved by the Ethics Committee of our Institution 1 
(N° of approval: 2013_06_25) and all eligible subjects received both verbal and written 2 
information about the study. All participants signed an informed consent, according to the 3 
Declaration of Helsinki.  4 
 5 
Cognitive and Psychological Assessment 6 
The Italian version of the ECAS was administered (15), assessing different cognitive 7 
domains, including ALS-Specific and ALS Non-specific tasks. When possible, the mode of 8 
testing (spoken or written) was maintained for the longitudinal screens. Moreover, caregivers 9 
longitudinally performed the ECAS Behaviour Interview (see Poletti et al. (15) for further 10 
details about the procedure adopted); both the number of behavioural symptoms (ECAS 11 
Behaviour Interview-Symptoms) and the global score obtained (ECAS Behaviour Interview-12 
Total score) were recorded.  13 
The study protocol also included two widely used screening tools, i.e. the Frontal Assessment 14 
Battery (FAB) (41) and the Montreal Cognitive Assessment (MoCA) (42), that were 15 
administered at T0 and at any follow-up, when possible, and the Frontal Behavioural 16 
Inventory (FBI), assessing behavioural alterations (43). To explore the relationship between 17 
ECAS performance and psychological factors, participants completed the Beck Depression 18 
Inventory (BDI) (44) and the State-Trait Anxiety Inventory-Y (STAI-Y) (45), for depressive 19 
and anxiety evaluation, respectively.  20 
 21 
Statistical analyses  22 
To compare the scores between the longitudinal follow-ups, ANOVA for repeated measures 23 
were used followed by a posteriori contrasts when applicable. Otherwise the comparison was 24 
performed using Friedman’s test followed by Wilcoxon signed rank test with continuity 25 
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correction; for discrete variables McNemar test was applied. Benjamini and Hochberg False 1 
Discovery Rate was used as correction for multiple testing. Finally, Pearson’s correlation 2 
coefficient was used to assess the degree of association between measures. An α level of 0.05 3 
was considered for all hypothesis tests. All data analyses were performed using SAS 9.2 4 
software (SAS Institute, Cary, NC, USA). 5 
 6 
Results 7 
Patients’ demographic characteristics and reasons for attrition are depicted in Figure 1. 8 
Performance of 168 patients at T0, 48 patients at T1 and 18 patients at T2 are summarized in 9 
Supplementary Table 1.  10 
Nine out of 168 patients (5%)  had to use the written version at T0 due to severe dysarthria and 11 
five out of the 48 patients who completed the T1 evaluation (10%) had to switch to the written 12 
version at 6-months follow-up. The proportion of ALS patients for which it was necessary to 13 
change to the written version did not increase at 12- and 24-months follow-ups. The 14 
cognitive-behavioural performance in the ECAS of patients within the local geographical 15 
region who dropped out was analysed (see Supplementary Table 2 for details); results 16 
revealed that 38% of them presented with behavioural alterations and met the new revised 17 
criteria for ALS with behavioural impairment (ALSbi) (46) basing on ECAS performance at 18 
their last evaluation, while 32% could be classified for ALS with cognitive impairment 19 
(ALSci) and 13% as ALS with combined cognitive and behavioural impairment (ALScbi). 20 
 21 
Longitudinal ECAS in ALS patients 22 
No statistically significant difference was found between any ECAS score from T0 to T1 in the 23 
48 patients who performed the ECAS after 6 months from baseline [Table 1 near here].  24 
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When considering the subgroup who performed all the three assessments at T0, T1 and T2 1 
(N=18), results from ANOVA demonstrated a significant increase in ECAS Total and ALS 2 
Non-specific scores among the three follow-ups; in particular, post-hoc analysis revealed a 3 
significant increase from T0 to T2 (ECAS Total: p=0.058; ALS Non-specific: p=0.004), as 4 
well as from T1 to T2 (ECAS Total: p=0.027; ALS Non-specific: p=0.011). Moreover, the 5 
score obtained at the Memory subdomain globally increased among the three assessments, in 6 
particular between T0 and T1 (p=0.039) and between T0 and T2 (p=0.012), with patients 7 
showing a significantly higher score at the Immediate Recall task globally among the three 8 
follow-ups and particularly between T1 and T2 (p=0.029) [Table 2 near here].   9 
Of 168 patients, 37% met criteria for ALSci (46) at T0 and 31% of 48 patients were classified 10 
as ALSci at T1. No patients met criteria for ALS-FTD at any follow-up. When considering the 11 
18 patients who performed all the three assessments,6 (33%) met criteria for ALSci at T0, 5 12 
(28%) were classified as ALSci at T1 and 6 (33%) at T2. No significant difference was 13 
detected over time in the percentage of patients classified as ALSci. 14 
 15 
Behavioural changes 16 
At baseline and at T1, the majority of patients showed no relevant behavioural impairment or 17 
dysfunction detected across only one behavioural domain at the ECAS Behaviour Interview. 18 
Between 40-50% of patients showed evidence of behavioural changes meeting criteria for 19 
ALSbi at T0 (41%) and T1 (50%), while 33% of patients was classified as ALSbi at T2. 20 
Moreover, 12% of ALS patients was classified as ALScbi at T0, 21% at T1 and 22% at T2. 21 
Apathy/Inertia was the most represented symptom (34% at T0, 42% at T1, 33% at T2), 22 
followed by Loss of Sympathy/Empathy at T0 and T1, while at T2 Loss of 23 
Sympathy/Empathy, Behavioural Disinhibition and Change in Eating Behaviour were equally 24 
recorded as the most frequent dysfunctions (11%) after Apathy/Inertia. Data about the 25 
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distribution of behavioural dysfunctions at the ECAS Behaviour Interview across each 1 
follow-up are reported in Figure 2. Five patients at T0 (3%), three at T1 (6%) and none at T2 2 
had psychotic features; in all cases the only reported symptom was suspiciousness.  3 
When considering the subgroup who completed all the three assessments, no significant 4 
increase in behavioural symptoms was detected neither at the ECAS Behaviour Interview-5 
Symptoms (p=0.716), nor at the global score obtained at the ECAS Behaviour Interview-Total 6 
Score (p=0.065).   7 
Strong correlations were found between both the number of symptoms and the total score at 8 
the ECAS Behaviour Interview and FBI-A, FBI-B and FBI Total score at any follow-up 9 
[Table 3 near here].   10 
In the 48 patients who performed the ECAS twice (i.e. after 6 months from baseline), a 11 
significant increase of FBI Total Score and FBI-A was detected between T0 and T1 (FBI 12 
Total: p=0.036; FBI-A: p=0.056). Concerning the subgroup that completed all the three 13 
assessments, a significant increase of FBI Total Score could be globally detected (p=0.038); 14 
in particular, higher scores were found at T2 with respect to T0, but which did not reach 15 
statistical significance (p=0.075).  16 
Focusing on the relationship between behavioural alterations in the ECAS Behaviour 17 
Interview and cognitive performance, the ECAS Behaviour Interview-Symptoms negatively 18 
correlated with ECAS Total, ALS-Specific and ALS Non-Specific scores  only at T2 (see 19 
Table 4). On the contrary, no correlations were found between the ECAS Behavioural 20 
Interview-Total Score and the ECAS subscores nor at T0, T1 or T2. With concern to the FBI, 21 
no significant correlations were found at T0 and T1 between FBI-A, FBI-B and FBI Total 22 
score and any ECAS cognitive subscore, while at T2 significant negative correlations of FBI-23 
A and FBI Total scores were found with the ECAS Total, ALS-Specific  and ALS Non-24 




Longitudinal FAB and MoCA assessment in ALS patients 2 
All patients were able to complete the ECAS without any difficulties at T1. Even after 12–24 3 
months, the ECAS was still feasible as indicated by completion of the full test by all of the 4 
patients bar one who performed these assessments. In contrast, the FAB was administrable 5 
only in 71% of patients at T1 and in 67% of patients at T2. With the MoCA, only 69% of 6 
patients could perform it at T1 and 72% of patients completed it at T2. Patients showed neither 7 
a significant deterioration nor improvement in the FAB and MoCA scores at T1 and T2, when 8 
considering the patients’ subgroup who completed all the three assessments. 9 
 10 
Clinical and affective status 11 
No significant correlations were found between ECAS scores and disease duration or 12 
ALSFRS-R scores at any follow-up. Similarly, no correlations were found between disease 13 
duration and the number of behavioural symptoms or the ECAS Behaviour Interview-Total 14 
score at the carer interview.  15 
With concern to psychological aspects, of the 154 patients who completed the BDI at T0, 100 16 
(65%) showed scores indicative of clinically significant depression, ranging from mild-to-17 
moderate (66%), moderate-to-severe (26%) and severe (8%). At T1, 33 out of 47 patients 18 
(70%) showed some degree of depression, while at T2 11 out of 17 patients (65%) showed 19 
depressive symptoms. In the subgroup that completed all the three follow-ups, no significant 20 
differences were found between T0, T1 and T2. Patients did not show clinically relevant state 21 
and trait anxiety levels neither at T0, nor at T1 and T2; moreover, no significant differences 22 
concerning anxiety emerged across the serial follow-ups, when considering the patients’ 23 




Relationship to genetic profile 1 
At T0 three (19%) of the 16 patients presenting with C9orf72 repeat expansions performed 2 
abnormally on the ECAS Total, ALS-Specific and ALS Non-specific functions scores, while 3 
two (12.5%) were impaired at the ECAS Total and ALS-Specific functions scores. The 4 
remaining eleven patients (69%) showed normal cognitive performances. Six of 16 C9orf72 5 
patients (37,5%) who performed the study at T0 and one of the two patients who performed it 6 
at T2 met criteria for ALSbi, while none of the five C9orf72 patients who performed the 7 
ECAS at T1 showed cognitive impairment. Moreover, six of 16 patients at T0, two of 5 at T1 8 
and one of two at T2 were classified as ALSbi, while three patients at T0 and one at T2 met 9 
criteria for ALScbi. None of the C9orf72 patients showed psychotic abnormalities at any 10 
follow-up.  11 
 12 
Discussion  13 
Longitudinal neuropsychological studies of ALS are plagued by difficulties in assessing 14 
patients with progressive physical disability. The lack of use of cognitive tools 15 
accommodating for verbal-motor disability is one of the reason for the sparse and often 16 
conflicting data. Our work represents the first Italian longitudinal study assessing both 17 
cognitive and behavioural performance in ALS patients through the use of a multi-18 
dimensional screening test able to compensate for verbal-motor disability. All patients bar one 19 
were able to complete the whole ECAS. In contrast, the FAB was not administrable in about 20 
30% of patients at 6 and 12 months; comparable data were also obtained for the MoCA. Such 21 
findings are to be explained by the presence of subtasks involving motor and verbal skills and 22 
not accommodating for physical disability, thus confirming previous literature data (15, 33, 23 




Longitudinal cognitive changes 1 
The Italian ALS population showed no significant changes in ECAS scores from baseline to 2 
6-months follow-up. After 12 months, our patients’ subgroup who performed all the three 3 
evaluations achieved a significant improvement in some scores (ECAS Total, ALS Non-4 
specific and Memory subdomain), thus presenting a possible practice effect. In contrast, 5 
Burkhard et al. (33) did not find any practice effect in an ALS cohort, although this was found 6 
in healthy controls. Such conflicting results could be attributed to our larger sample size, 7 
rather than to other factors such as age, education or disease duration. Our results seem to 8 
support a well-known phenomenon in neuropsychological assessment underlining the 9 
presence of potential practice effects or initial unfamiliarity with test situation when patients 10 
are assessed repeatedly (48, 49); such an issue has been poorly investigated in ALS and few 11 
results are available (28). Recently, in order to overcome this issue, alternate forms of the 12 
ECAS have been developed (ECAS B and C) (50, 51). Repeated serial administration of the 13 
ECAS original version over a short time period produced improved scores for ALS-Specific, 14 
ALS Non-specific and ECAS Total scores, whereas such effects were not found when ECAS 15 
alternate versions were administered serially. The current study demonstrates that these 16 
practice effects can last over longer months, particularly in relation to the memory domain.  17 
 18 
Longitudinal behavioural changes 19 
No increase was observed in the number of behavioural symptoms detected at the ECAS 20 
Behaviour Interview, nor at the ECAS Behaviour Interview-Total Score within 12 months. In 21 
line with recent literature, Apathy/Inertia and Loss of Sympathy/Empathy were the more 22 
frequently observed changes (52, 53); furthermore, at 12 months also Behaviour Disinhibition 23 
and Change in Eating Behaviour became prominent in our cohort. Our data are partially in 24 
contrast with previous results indicating a slight progression of behavioural alterations at the 25 
13 
 
ECAS over time (33). However, when considering the FBI scores, an increment of 1 
behavioural dysfunction was longitudinally found, thus confirming the possible progression 2 
of behavioural features in ALS. Such contrasting data about the longitudinal changes detected 3 
at ECAS Behaviour Interview and FBI, as well as the relationship with cognitive performance 4 
at the ECAS, could be explained by the fact that, unlike the FBI, the ECAS Behaviour 5 
Interview has been designed to diagnose ALSbi and/or ALS-FTD and scores the 6 
presence/absence of a behavioural dysfunction, not measuring its severity. Behavioural 7 
dysfunction also emerged as a prominent feature characterising our dropped-out patients, thus 8 
highlighting the need to consider these symptoms in ALS patients’ clinical management.      9 
The lack of significant correlations of disease duration and ALSFRS-R with ECAS 10 
cognitive/behavioural performance is in line with previous literature data (54, 55).    11 
Depressive symptoms are prevalent in ALS; however, worsening depression was not observed 12 
in our sample during follow-ups, as previously recorded (56, 57). In contrast, no clinically 13 
relevant anxiety levels were found at serial investigations, in accordance to previous results 14 
(58-60).  15 
 16 
Longitudinal cognitive-behavioural performance and genetic profile    17 
Despite recent literature having confirmed the high prevalence of cognitive-behavioural 18 
impairment in patients with C9orf72 repeat expansions (39, 30, 61), only a small proportion 19 
of our mutated ALS patients showed such alterations. However, our data could possibly be 20 
explained by the small number of mutation carriers who completed the follow-up evaluations 21 
in our sample cohort. 22 
More generally, the high drop-out rate of patients during the serial follow-up and the resulting 23 
small sample size, also with regard to genetic data, represent a limitation of our study, 24 
14 
 
together with a bias towards slow progressors and long survivors, thus suggesting the need to 1 
enlarge these cohorts in future analyses.  2 
 3 
Conclusion 4 
In summary, our results support the use of the ECAS also in moderate and advanced stages of 5 
the disease, in order to assess cognitive-behavioural progression in ALS. Our ALS Italian 6 
population showed no significant cognitive deterioration at ECAS performance between serial 7 
evaluations; on the contrary, we detected a significant improvement between baseline and 12-8 
months assessment at some ECAS scores. No increase of behavioural changes over time was 9 
recorded at the ECAS Behaviour Interview even if such changes were detected when 10 
measured by FBI, thus suggesting a possible progression of behavioural features in ALS. 11 
Moreover, behaviour impairment emerged as a prominent issue characterising our drop-outs, 12 
further underlining its critical role in clinical management of ALS patients. Despite the above 13 
mentioned limitations, the present work represents the first Italian follow-up study performed 14 
with the new gold standard for cognitive/behavioural screen in ALS. Accommodating for 15 
verbal-motor components represents a crucial issue for ALS longitudinal assessment. The 16 
implementation of Italian ECAS alternate forms represents a future challenge, in order to 17 
minimize the presence of possible unfamiliarity/practice effect bias and will help to better 18 
describe ALS patients’ phenotypes along the course of the disease.   19 
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Supplementary Table 1. Mean performance of ALS patients at T0, T1 and T2 on the ECAS 2 
subdomains and Total score, FAB and MoCA. Number of patients cognitively and/or 3 
behaviourally impaired are also reported 4 
Supplementary Table 2. Number of dropped out patients who were classified as cognitively 5 
and/or behaviourally impaired at the last evaluation performed 6 
 7 
Tables 8 
Table 1. Longitudinal performance on the ECAS subdomains and Total score, FAB and MoCA of the 9 
48 ALS patients who completed the ECAS at T0 and T1. Data are expressed as means (standard 10 
deviations).  11 
 Baseline (T0) N=48 
6 months (T1) 




functions 34.25 (6.25) 34.29 (7.60) 0.952 
Language  
functions 23.54 (3.68) 24.02 (3.36) 0.143 
Fluency 17.13 (4.95) 16.92 (5.47) 0.711 
Memory  
functions 14.60 (4.60) 15.42 (4.50) 0.059 
Visuospatial 
functions 11.38 (0.89) 11.40 (1.30) 0.921 
ALS-Specific  
Functions 74.92 (11.79) 75.23 (13.12) 0.753 
ALS Non-specific  
Functions 25.98 (4.75) 26.81 (5.04) 0.053 
ECAS  
Total Score 100.90 (15.11) 102.04 (17.07) 0.286 
FAB 15.93 (1.51) 16.13 (1.45) 0.589 
MoCA 24.35 (3.09) 24.15 (3.55) >0.999 
Bold numbers indicate statistical significance with p < 0.05. FAB: Frontal Assessment Battery; MoCA: Montreal 12 
Cognitive Assessment. 13 
 14 
Table 2. Longitudinal performance on the ECAS subdomains and Total score, of the ALS patients 15 
subgroup (n=18) who completed the three assessments. Data are expressed as means (standard 16 
deviations).    17 
 Baseline (T0) N=18 
6 months (T1) 
N=18 








Executive functions 36.17 (5.35) 34.61 (8.98) 37.83 (4.55) 0.230 
Language functions 23.78 (3.84) 23.72 (3.44) 24.33 (3.50) 0.505 
Fluency 17.67 (5.46) 17.89 (5.29) 17.00 (5.58) 0.423 
Memory functions 13.72 (5.07) 14.39 (5.50)* 16.39 (4.68)* 0.011 
Visuospatial functions 11.28 (0.89) 11.17 (1.72) 11.50 (0.86) 0.289 
ALS-Specific Functions 77.83 (12.24) 76.06 (14.55) 79.17 (11.43) 0.125 
ALS Non-specific 
Functions 25.00 (5.18) 25.56 (6.32) 27.89 (4.71)*,
§ 0.003 
ECAS Total Score 102.83 (16.42) 101.61 (20.12) 107.06 (15.76)*,§ 0.023 
Bold numbers indicate statistical significance with p < 0.05. * p<0.05 vs T0; § p<0.05 vs T1 1 
 2 
Table 3. Correlations between ECAS Carer Interview (number of symptoms and total score) and FBI 3 
at T0, T1 and T2. 4 
  
T0 T1 T2 
  




























































Table 4. Correlations between ECAS Carer Interview (number of symptoms and total score) and FBI and cognitive performance at the ECAS at T0, T1 and T2. 1 
  
T0 T1 T2 


































































































































Bold numbers indicate statistical significance with p < 0.05. ECAS Behav Interview – Symptom: ECAS Behaviour Interview – number of symptoms; ECAS Behav Interview – Tot: ECAS 2 
Behaviour Interview – Total Score; FBI: Frontal Behaviour Inventory.  3 
 4 
